Supplementary Methods, Figure Legends 1-5, Table Legends 1-3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389585.v1

2023-01-01

Abstract:PDF file - 121K

What problem does this paper attempt to address?

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528440.v1

2023-01-01

Abstract:PDF file, 125K, Western blot of total PARP1.
Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528425

2023-01-01

Abstract:PDF file, 64K, Non-small cell lung cancer cell lines.
Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai Tran,Robert J.G. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun K. Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22446704

2023-01-01

Abstract:PDF file - 66K, CDH1 probes vary in their accuracy and dynamic range
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced let-7g Expression in Breast Cancer Invasion and Metastasis

Pengxu Qian,Zehua Zuo,Zhengsheng Wu,Xianyi Meng,Gaopeng Li,Zhengzhou Wu,Weijie Zhang,Sheng Tan,Vijay Pandey,Yandan Yao,Puyue Wang,Liqing Zhao,Jun Wang,Qiang Wu,Erwei Song,Peter E. Lobie,Zhinan Yin,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.22391054

2023-01-01

Abstract:PDF file - 214K
Supplementary Data Legends and Methods from Novel Oncogene–Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures

Xiaoming Ju,Adam Ertel,Mathew C. Casimiro,Zuoren Yu,Hua Meng,Peter A. McCue,Robin G. Walters,Paolo Fortina,Michael P. Lisanti,Richard G. Pestell

DOI: https://doi.org/10.1158/0008-5472.22396404

2023-01-01

Abstract:PDF file - 132KB, Legends for Supplementary Table 1 and Figures 1-7, and Supplementary Methods
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplementary Figure Legends 1-4, Methods from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Nicolaos Palaskas,Steven M. Larson,Nikolaus Schultz,Evangelia Komisopoulou,Justin Wong,Dan Rohle,Carl Campos,Nicolas Yannuzzi,Joseph R. Osborne,Irina Linkov,Edward R. Kastenhuber,Richard Taschereau,Seema B. Plaisier,Chris Tran,Adriana Heguy,Hong Wu,Chris Sander,Michael E. Phelps,Cameron Brennan,Elisa Port,Jason T. Huse,Thomas G. Graeber,Ingo K. Mellinghoff

DOI: https://doi.org/10.1158/0008-5472.22388192

2023-01-01

Abstract:Supplementary Figure Legends 1-4, Methods from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Tao Zuo,Ta-Ming Liu,Xun Lan,Yu-I Weng,Rulong Shen,Fei Gu,Yi-Wen Huang,Sandya Liyanarachchi,Daniel E. Deatherage,Pei-Yin Hsu,Cenny Taslim,Bhuvaneswari Ramaswamy,Charles L. Shapiro,Huey-Jen L. Lin,Alfred S. L. Cheng,Victor X. Jin,Tim H.-M. Huang

DOI: https://doi.org/10.1158/0008-5472.22389515.v1

2023-01-01

Abstract:Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer
Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404374

2023-01-01

Abstract:Supplementary Materials and Methods, Supplementary Figure Legends, and Characteristics of primary human pediatric T-ALL samples (Supplementary Table S1).
Supplementary Figure Legends 1-10, Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Daniel Braas,Ethan Ahler,Brenna Tam,David Nathanson,Mirielle Riedinger,Matthias R. Benz,Kathleen B. Smith,Fritz C. Eilber,Owen N. Witte,William D. Tap,Hong Wu,Heather R. Christofk

DOI: https://doi.org/10.1158/2159-8290.22529049

2023-01-01

Abstract:PDF file - 95K, Supplemental Figure 10: PBS treatment does not affect tumor growth of scramble- and dCK-knockdown liposarcomas.
Supplementary Figure Legends 1-2 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Michael A. Davies,Patricia S. Fox,Nicholas E. Papadopoulos,Agop Y. Bedikian,Wen‐Jen Hwu,Alexander J. Lazar,Víctor G. Prieto,Kirk S. Culotta,Timothy Madden,Qiang Xu,Sha Huang,Wanleng Deng,Chaan S. Ng,Sanjay Gupta,Wenbin Liu,Janet Dancey,John Wright,Roland L. Bassett,Patrick Hwu,Kevin B. Kim

DOI: https://doi.org/10.1158/1078-0432.22444286

2023-01-01

Abstract:PDF file - 85K
Supplementary Figures and Figure Legends from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Tao Yu,Yingjun Zhao,Zhixiang Hu,Jing Li,Dandan Chu,Jiwei Zhang,Zhe Li,Bing Chen,Xiao Zhang,Hongyu Pan,Shengli Li,Hechun Lin,Lei Liu,Mingxia Yan,Xianghuo He,Ming Yao

DOI: https://doi.org/10.1158/0008-5472.22418432.v1

2023-01-01

Abstract:Supplementary Figures and Figure legends that contain the information of the characteristics of MetaLnc9 in NSCLC, Non-coding RNA analysis, the efficiency for MetaLnc9 overexpression and Knockdown, the molecular mechanism of PGK1 and NONO.
Supplementary Figures and Legends from Targeting PRPK Function Blocks Colon Cancer Metastasis

Tatyana Zykova,Feng Zhu,Lei Wang,Haitao Li,Do Young Lim,Ke Yao,Eunmiri Roh,Sang-Pil Yoon,Hong-Gyum Kim,Ki Beom Bae,Weihong Wen,Seung Ho Shin,Janos Nadas,Yan Li,Weiya Ma,Ann M. Bode,Zigang Dong

DOI: https://doi.org/10.1158/1535-7163.22504792.v1

2023-01-01

Abstract:This file contains 7 Supplementary Figures and associated legends: Supplementary Figure 1. Characterization of the antibody to detect phosphorylated Ser250of PRPK (related to Figure 1B, upper). Supplementary Figure 2. PRPK induces metastasis of colon cancer cells to the liver. Supplementary Figure 3. PRPK induces lung metastasis of human HCT116 or mouse CT26 colon cancer cells. Supplementary Figure 4. EGF induces phosphorylation of PRPK and surviving ex vivo and the combination of 5-FU and FA show synergistic effects against colon cancer growth. Supplementary Figure 5. Pre-treatment with FA combined with 5-FU suppresses colon lung metastasis in mice. Supplementary Figure 6. FA combined with 5-FU suppresses colon lung metastasis in mice Supplementary Figure 7. PRPK regulated colon cancer metastasis independently of p53 status.
Supplementary Materials and Methods from Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in &Lt;i>pik3ca-Mutant Colorectal Cancer

Samuel A. Miller,Robert A. Policastro,Sudha S. Savant,Shruthi Sriramkumar,Ning Ding,Xiaoyu Lu,Helai P. Mohammad,Sha Cao,Jay H. Kalin,Philip A. Cole,Gabriel E. Zentner,Heather M. O’Hagan

DOI: https://doi.org/10.1158/1541-7786.22516897.v1

2023-01-01

Abstract:Contains additional details on bioinformatic analyses, including references for packages used.
Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Hong-Lin Jiang,He-Fen Sun,Shui-Ping Gao,Liang-Dong Li,Sheng Huang,Xin Hu,Sheng Liu,Jiong Wu,Zhi-Ming Shao,Wei Jin

DOI: https://doi.org/10.1158/0008-5472.22409469.v1

2023-01-01

Abstract:Supplementary Materials and Methods, Supplementary Figure Legends, Supplementary Table S1 Alteration of SSBP1 protein expression levels in relation to clinicopathological characteristics in breast cancer patients. Supplementary Table S2 Antibodies used in this study. Supplementary Table S3 Primers for plasmid construction. Supplementary Table S4 Primers for ChIP. Supplementary Table S5 iTRAQ: Dysregulated proteins with gene symbol.
Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Peng Yuan,Xiao-Hong He,Ye-Fei Rong,Jing Cao,Yong Li,Yun-Ping Hu,Yingbin Liu,Dangsheng Li,Wenhui Lou,Mo-Fang Liu

DOI: https://doi.org/10.1158/0008-5472.22413540

2023-01-01

Abstract:This file contains Materials and Methods that are involved in the figures of the main text and supplementary information. These materials and methods include information of plasmid constructs, cell transfection and viral transduction, RNA preparation and qRT-PCR, luciferase reporter assay, ChIP assay, therapeutic experiments in mice, and immunohistochemistry and in situ hybridization.

Supplementary Methods, Figure Legends 1-5, Table Legends 1-3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Data Legends and Methods from Novel Oncogene–Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure Legends 1-4, Methods from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure Legends 1-10, Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figure Legends 1-2 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Supplementary Figures and Figure Legends from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Supplementary Figures and Legends from Targeting PRPK Function Blocks Colon Cancer Metastasis

Supplementary Materials and Methods from Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in &Lt;i>pik3ca</i>-Mutant Colorectal Cancer

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Methods, Figure Legends 1-5, Table Legends 1-3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced &lt;i&gt;let-7g&lt;/i&gt; Expression in Breast Cancer Invasion and Metastasis

Supplementary Data Legends and Methods from Novel Oncogene–Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure Legends 1-4, Methods from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure Legends 1-10, Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figure Legends 1-2 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Supplementary Figures and Figure Legends from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Supplementary Figures and Legends from Targeting PRPK Function Blocks Colon Cancer Metastasis

Supplementary Materials and Methods from Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in &Lt;i&gt;pik3ca&lt;/i&gt;-Mutant Colorectal Cancer

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figure Legends 1-4, Methods from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Materials and Methods from Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in &Lt;i>pik3ca</i>-Mutant Colorectal Cancer